See more : Bank Norwegian Asa (BANO.OL) Income Statement Analysis – Financial Results
Complete financial analysis of Altamira Therapeutics Ltd. (CYTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Altamira Therapeutics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MEDINET Co., Ltd. (2370.T) Income Statement Analysis – Financial Results
- BrightSpring Health Services, Inc. Common Stock (BTSG) Income Statement Analysis – Financial Results
- Empress Royalty Corp. (EMPYF) Income Statement Analysis – Financial Results
- KITAC Corporation (4707.T) Income Statement Analysis – Financial Results
- Element 25 Limited (ELMTF) Income Statement Analysis – Financial Results
Altamira Therapeutics Ltd. (CYTO)
About Altamira Therapeutics Ltd.
Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 305.62K | 63.88K | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 1.44M | 2.24M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -1.14M | -2.18M | 174.48K | -56.00K | 1.27M | 322.00K | -414.00K | -67.00K | 3.01M | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | -372.44% | -3,407.33% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 3.04M | 19.68M | 8.94M | 2.86M | 3.33M | 6.69M | 19.21M | 24.78M | 26.54M | 17.70M | 13.25M | 3.99M |
| General & Administrative | 3.09M | 3.52M | 4.90M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Selling & Marketing | 15.35K | 2.38M | 1.50M | 95.66K | 113.96K | 43.82K | 199.48K | 45.65K | 72.56K | 237.72K | 479.03K | 86.23K |
| SG&A | 3.12M | 5.90M | 6.39M | 2.59M | 3.93M | 4.26M | 5.15M | 5.41M | 4.34M | 4.49M | 1.31M | 589.53K |
| Other Expenses | 0.00 | -586.73K | -409.93K | 0.00 | 0.00 | 215.72K | 87.59K | 34.06K | 62.20K | 73.43K | 49.42K | 34.28K |
| Operating Expenses | 6.54M | 24.99M | 14.92M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Cost & Expenses | 6.54M | 26.44M | 17.16M | 5.46M | 7.26M | 10.95M | 24.36M | 30.22M | 30.88M | 22.19M | 14.62M | 4.61M |
| Interest Income | 730.20K | 969.00 | 3.22K | 258.00 | 17.88K | 0.00 | 53.57K | 67.57K | 37.00K | 52.13K | 74.04K | 5.83K |
| Interest Expense | 0.00 | 911.87K | 189.70K | 135.15K | 28.63K | 1.07M | 1.64M | 828.55K | 8.00K | 49.64K | 50.18K | 0.00 |
| Depreciation & Amortization | 5.92M | 118.89K | 76.36K | 20.04K | 30.82K | 72.71K | 122.78K | 97.60K | 92.78K | 73.98K | 37.52K | 9.24K |
| EBITDA | -1.35M | -17.64M | -6.72M | -5.26M | -7.24M | -10.95M | -24.31M | -30.06M | -30.84M | -22.19M | -14.51M | -4.60M |
| EBITDA Ratio | 0.00% | -8,511.54% | -26,643.21% | -3,027.89% | 12,930.83% | -865.25% | -7,548.97% | 7,260.41% | 46,031.34% | -737.55% | 0.00% | 0.00% |
| Operating Income | -5.92M | -26.13M | -17.10M | -5.28M | -7.26M | -10.95M | -24.36M | -30.22M | -30.88M | -22.19M | -14.62M | -4.61M |
| Operating Income Ratio | 0.00% | -8,550.76% | -26,767.78% | -3,028.04% | 12,962.76% | -865.25% | -7,565.61% | 7,300.31% | 46,086.57% | -737.59% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.35M | -645.64K | -1.46M | -2.94M | 433.41K | -380.10K | -66.00K | -570.03K | 1.17M | 4.01M | -82.89K | 8.09K |
| Income Before Tax | -7.27M | -26.54M | -17.37M | -8.22M | -6.83M | -11.33M | -24.43M | -30.79M | -29.71M | -18.19M | -14.70M | -4.60M |
| Income Before Tax Ratio | 0.00% | -8,683.69% | -27,188.48% | -4,712.11% | 12,188.82% | -895.28% | -7,586.10% | 7,438.00% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -10.33K | 21.62K | -21.28K | -193.84K | 162.18K | -17.77K | -131.06K | -84.78K | -892.18K | 305.75K | 0.00 |
| Net Income | -7.27M | -26.53M | -17.39M | -8.20M | -6.63M | -11.50M | -24.41M | -30.66M | -29.71M | -18.19M | -15.00M | -4.60M |
| Net Income Ratio | 0.00% | -8,680.31% | -27,222.33% | -4,699.91% | 11,842.68% | -908.09% | -7,580.58% | 7,406.34% | 44,335.82% | -604.35% | 0.00% | 0.00% |
| EPS | -14.81 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| EPS Diluted | -14.80 | -582.58 | -525.13 | -545.41 | -455.96 | -2.89K | -22.32K | -35.73K | -36.79K | -26.27K | -33.25K | -10.20K |
| Weighted Avg Shares Out | 491.00K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
| Weighted Avg Shares Out (Dil) | 491.26K | 45.54K | 33.12K | 15.04K | 14.55K | 3.98K | 1.09K | 858.20 | 807.40 | 692.30 | 451.30 | 451.30 |
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
Hamilton, Bermuda, Aug. 23, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO) today announced that its associate company Altamira Medica Ltd. has agreed with its Norwegian partner Pharma Nordic AS (“Pharma Nordic”) to extend the territory...
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) -- Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the...
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
Hamilton, Bermuda, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the publication of a peer-reviewed article in...
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
Hamilton, Bermuda, July 19, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced the preprint publication of a study demonstrating...
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
Hamilton, Bermuda, June 20, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today highlighted the publication of an article describing the...
Altamira Therapeutics Provides Business Update
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 28, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today provided...
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMIL TON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced...
Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation
Hamilton, Bermuda, May 01, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA / May 1, 2024 / Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced...
Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal
Hamilton, Bermuda, April 24, 2024 (GLOBE NEWSWIRE) -- HAMIL TON, BERMUDA -- April 24 , 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today...
Altamira Therapeutics Ltd. (CYTO) Q4 2023 Earnings Call Transcript
Altamira Therapeutics Ltd. (NASDAQ:CYTO ) Q4 2023 Earnings Conference Call April 10, 2024 8:30 AM ET Company Participants Thomas Meyer - Founder, Chairman & Chief Executive Officer Covadonga Pañeda - Chief Operating Officer Operator Good morning, and welcome to the...
Source: https://incomestatements.info
Category: Stock Reports